Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Neon data highlights epitope spread as key metric for neoantigen vaccines

March 31, 2019 7:31 PM UTC

Interim results from Neon's Phase Ib trial of NEO-PV-01 plus Opdivo nivolumab suggest proof of epitope spread will be a telling readout for neoantigen cancer vaccines. The data also point to tumor microenvironment-based predictors of therapeutic response.

Clinical data trickling in from early movers like Neon Therapeutics Inc. (NASDAQ:NTGN) could define biomarkers and set benchmarks for the crowded neoantigen vaccine field (see "Neo Wave")...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Neon Therapeutics Inc.